Subclassification of the “Grey Zone” of Thyroid Cytology; A Retrospective Descriptive Study with Clinical, Cytological, and Histological Correlation
Author(s) -
Mariella Bonzanini,
Pierluigi Amadori,
Luca Morelli,
Silvia Fasanella,
Riccardo Pertile,
Angela Mattiuzzi,
Giorgio Marini,
Mauro Niccolini,
Giuseppe Tirone,
Marco Rigamonti,
Paolo Palma
Publication year - 2011
Publication title -
journal of thyroid research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 31
eISSN - 2090-8067
pISSN - 2042-0072
DOI - 10.4061/2011/251680
Subject(s) - medicine , cytology , thyroid , pathology , general surgery
Undetermined thyroid cytology precludes any definitive distinction between malignant and benign lesions. Recently several classifications have been proposed to split this category into two or more cytological subcategories related to different malignancy risk rates.The current study was performed retrospectively to investigate the results obtained separating “undetermined” cytologic reports into two categories: “follicular lesion” (FL) and “atypia of undetermined significance” (AUS). Biochemical, clinical, and echographic features of each category were also retrospectively analyzed. Altogether, 316 undetermined fine-needle aspirated cytologies (FNACs) were reclassified as 74 FL and 242 AUS. Histological control leads to a diagnosis of carcinomas, adenomas, and nonneoplastic lesions, respectively, in 42.2%, 20%, and 37.8% of AUS and in 8.3%, 69.4%, and 22.2% of FL. Among biochemical, clinical, cytological, and echographic outcomes, altered thyroid autoantibodies, multiple versus single nodule, AUS versus FL, and presence of intranodular vascular flow were statistically significant to differentiate adenoma from carcinoma and from nonneoplastic lesions, whereas no significant differences were found between carcinomas and nonneoplastic lesions for these parameters. The results of this retrospective study show that undetermined FNAC category can further be subclassified in AUS and FL, the former showing higher malignancy rate. Further prospective studies are needed to confirm our results
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom